Neogen Q3 FY26 revenue $211.2M; net loss $17M; divests Genomics unit

NEOGEN CORP

2026-Q3 EPS reported $0.02 revenue$645,100,000

Revenue $211.2M; Food Safety core growth +4.0%, Animal Safety core growth –8.7% on supplier challenges.
GAAP net loss $17.0M ($0.08 loss per share); Adjusted EPS $0.09; Adjusted EBITDA $48.2M (22.8% margin).
Divestiture of Genomics business announced, expected to close in Q2 FY27; proceeds to reduce leverage.
Raising FY2026 revenue outlook; maintaining Adjusted EBITDA guidance.
Petrifilm manufacturing transition on track for November FY27; validation on multiple SKUs started.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

NEOGEN CORP reported third quarter ended February 28, 2026 results: revenue $211.2 million, net income Net loss of $17.0 million, EPS GAAP EPS of $(0.08). Guidance raised.

Period: third quarter ended February 28, 2026
Revenue: $211.2 million
Net income: Net loss of $17.0 million
EPS: GAAP EPS of $(0.08)
Guidance: raised
Result: preliminary results

Exact text from the filing

language in the filing. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Neogen Reports Third Quarter Fiscal Year 2026 Financial Results • Fiscal third quarter 2026 revenue of $211.2 million • Food Safety revenue growth of 2.6%, Core Growth 1 of 4.0%; Animal Safety revenue growth of (20.1%), Core Growth 1 of (8.7%) due primarily to third-party supplier challenges in

View on SEC.gov

1349 earnings releases filed in the last 30 days. Browse all earnings releases →

NEOGEN CORP filing history →

Source: SEC EDGAR

accession 0001193125-26-148851

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.